Gilead’s Viread In HBV Shores Up Flagging Sales For Drug In HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Analyst suggests $300 million additional revenue from Viread’s HBV indication.
You may also be interested in...
FDA Clears Gilead’s Regulatory Path For Three New Chemical Entities In HIV
Also waiting for agency word on its appeal to a “complete response” letter for aztreonam lysine in cystic fibrosis.
FDA Clears Gilead’s Regulatory Path For Three New Chemical Entities In HIV
Also waiting for agency word on its appeal to a “complete response” letter for aztreonam lysine in cystic fibrosis.
Gilead Positioned To Benefit From Potential HIV Guidelines Change
Emerging data on initiating anti-retroviral treatment earlier in HIV patients could broaden the treatment-naïve market.